FIPI (hydrochloride)

FIPI hydrochloride is a phospholipase D (PLD) inhibitor with an IC50 for PLD1 and PLD2 of about 25 nM. FIPI hydrochloride regulates cytoskeletal recombination, cell diffusion and chemotaxis. FIPI hydrochloride can be used in cancer research. In addition, FIPI hydrochloride can enhance the secretion and aggregation of platelet dense particles, inhibit thrombosis, reduce ischemic stroke infarct volume and improve nerve function[1][2][3].

Product Specifications

CAS Number

[1781834-93-2]

Product Name Alternative

5-Fluoro-2-indolyl deschlorohalopemide (hydrochloride)

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

Phospholipase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology; Neurological Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/fipi-hydrochloride.html

Solubility

10 mM in DMSO

Smiles

O=C(NCCN1CCC(CC1)N2C3=CC=CC=C3NC2=O)C4=CC5=C(C=CC(F)=C5)N4.[H]Cl

Molecular Formula

C23H25ClFN5O2

Molecular Weight

457.93

Precautions

P261-P280-P302+P352

References & Citations

[1]Monovich L, et al. Optimization of halopemide for phospholipase D2 inhibition. Bioorg Med Chem Lett. 2007 Apr 15;17 (8) :2310-1.|[2]Claudia Dall'Armi, et al. The phospholipase D1 pathway modulates macroautophagy. Nat Commun. 2010:1:142.|[3]Su W, et al. 5-Fluoro-2-indolyl des-chlorohalopemide (FIPI), a phospholipase D pharmacological inhibitor that alters cell spreading and inhibits chemotaxis. Mol Pharmacol. 2009 Mar;75 (3) :437-46.